Remove Clinical Trials Remove Information Remove Patients Remove Topical
article thumbnail

CDC Seeks Public Comments Regarding Chronic Pain Management

NORML

CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” ” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. percent in 2016).”

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

article thumbnail

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS About Altasciences.

article thumbnail

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

Are you able to answer your patients’ medical marijuana questions? In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. million medical marijuana patients nationwide.

article thumbnail

Data Analysis Yields Insights Into Medical Cannabis Use, Efficacy

Cannabis Law Report

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. How to Use the Data.

Data 105